All News
Do different genders experience PsA differently?
There has been a lot of talk lately about the difference in the way male and female PsA patients experience their disease. Are the differences only cultural or are there important clinical differences in the disease presentation, organ involvement and complications that physicians should be aware of?
Read Article
Reproductive concerns of adolescent patients with rheumatic disease
Abstract #129 #ACR22 @RheumNow
🤰Worried about effects of dx and meds on fertility and pregnancy
💊Concerns about which birth control to use
🩸Effects of dx. on menstruation
Catherine Sims, MD DrCassySims ( View Tweet)
Kimbrough et al. Comorbidities assoc serious infection in RA. Many! 26/55 comorbidities assoc serious infection. Number of comorbidities also assoc HR 1.16 (1.13-1.19) @RheumNow #ACR22 Abstr#1950 https://t.co/gnIlaJ037B https://t.co/6SR2Ej584w
Richard Conway RichardPAConway ( View Tweet)
RA asso w/ higher risk of lung cancer aHR 1.53, also in non-smokers aHR 1.66 🚬
Now this risk increases even more in pts w/ RA-ILD 🫁
aHR 3.06
No adjustment on occupation or non tobacco inhaled toxic exposure
https://t.co/41ibPD6S3b
Abs#1647 #ACR22 @RheumNow https://t.co/LNw792MYV0
Aurelie Najm AurelieRheumo ( View Tweet)
Does Evusheld shield people living with rheumatic diseases? #ACR22
https://t.co/IutdoFxJUx https://t.co/FuKZEtpImm
Links:
Dr. John Cush RheumNow ( View Tweet)
#L02 #acr22 @rheumnow Bimekizumab ph3 in PsA: meaningful clinical improvement, improved mTSS, no new safety signals. Wk 52 ACR50: 53.0% PBO/BKZ, 54.5% BKZ, 50.0% ADA; MDA 53.7% PBO/BKZ, 55.0% BKZ, 52.9% ADA . mTSS change from baseline ≤0.5): 87.3% PBO/BKZ, 89.3% BKZ, 94.1% ADA https://t.co/NYRrPUBjt1
Olga Petryna DrPetryna ( View Tweet)
Yazici et al. IA Lorecivivint in Knee OA. 56 week DB-RCT of single injection at time 0. Didn't work. Not for primary endpoint (Pain NRS) or any PRO. @RheumNow #ACR22 Abstr#1639 https://t.co/66KyJW1zVz
Richard Conway RichardPAConway ( View Tweet)
Ultrasound and MRI have taught us a lot about PMR, but it's the power of PET/CT which illustrated the specific pathology of PMR in full color vision.
@drceowen #ACR22 @RheumNow https://t.co/N8hVjqpVwe
David Liew drdavidliew ( View Tweet)
14M111 Updated ACR Guidelines for Glucocorticoid-Induced Osteoporosis #ACR22 🦴🦴
Initial Fracture Risk Assessment - by age - remember: no FRAX scores <40 yo
Fracture re-assessments every 1-2 years with repeat BMD and risk stratifications
@RheumNow https://t.co/QlCVM1lDb0
Eric Dein ericdeinmd ( View Tweet)
BE OPTIMAL: BKZ in PsA Phase 3 RCT
Data at 52 wks 700+ completed study
ACR50: 53% PBO/BKZ, 54% BKZ, 50% ADA
PASI 100 65% PBO/BKZ, 61% BKZ, 48% ADA
No Rx progression 87% PBO/BKZ, 89% BKZ, 94% ADA
Candida infections 7% BKZ, 0.7% ADA
https://t.co/MMjN1Aa3qf
Abs#L02 #ACR22 @Rheumnow https://t.co/keF0QOZMwA
Aurelie Najm AurelieRheumo ( View Tweet)
Dr. B Humphrey #ACR22 #Osteoporosis Guidelines:
in patients under 40 yo, you cannot calculate #FRAX score, assess BMD and in children get also thoracolumbar xrays. Get repeat testing every 1-2 years #ACR22 @rheumnow https://t.co/CgsvzGKYuV
TheDaoIndex KDAO2011 ( View Tweet)
Get the skinny on Bimmy! Gotta learn this name #Bimekizumab in bio naive PsA N=852 Bimmy=IL17 A & F inhibitor Great data on skin & joints. Where will it fit in as we have other IL17Ai’s is IL17F giving added value? #ACR22 #ACRBest @RheumNow https://t.co/wNAzTaLhsM
Janet Pope Janetbirdope ( View Tweet)
800+ women w/ IMID & 1700+ ctrl w/ 6 yrs follow-up
All GC users < BMD levels
-4.2% > 2.5mg/d
-2.7% <2.5mg/d
Crude FX rate 4.8/100PY GC >= 5mg/d, 2.5/100PY GC < 2.5mg/d
🦴Fx incidence > IMID vs. Ctrls
GC use >= 5mg/d x2 risk of Fx
https://t.co/6sj77PwyYQ
Abs#L01 #ACR22 @Rheumnow https://t.co/OZhfuh0Jrm
Aurelie Najm AurelieRheumo ( View Tweet)
14M111 Updated ACR Guidelines for Glucocorticoid-Induced Osteoporosis #ACR22 🦴🦴
Reminder: Recalculate FRAX scores with scaling for prednisone equivalent dosing!
Use other clinical fracture risk assessments
@RheumNow https://t.co/qZDlb1Cij7
Eric Dein ericdeinmd ( View Tweet)
Dr. B Humphrey #ACR22 #Osteoporosis Guidelines:
FRAX needs to be adjusted according to the dose of GC's (7.5+ mg/day multiply FRAX score by 1.2)
#ACR22 @rheumnow https://t.co/U7IOjbTwxN
TheDaoIndex KDAO2011 ( View Tweet)
#L01 #acr22 @rheumnow chronic GC use in rheum Dx assoctd w/⬇️ T scores & ⬆️fracture even if dose 2.5 mg or less. GC use ≥5 mg/day associated w/ 2-fold higher risk of fracture of any kind compared to all other doses& controls (aHR 2.37, 95% CI 1.33-4.23).Preventable w/anti-OP Rx https://t.co/sCWkEBPMMT
Olga Petryna DrPetryna ( View Tweet)
Almayali et al. Follow-up of GLORIA study. Now tapering of the pred 5mg after 2 years. Small increase in disease activity (to same level as prev placebo), numerical increase in flare. No adrenal insufficiency @RheumNow #ACR22 Abstr#2000 https://t.co/5oclSdlXWA https://t.co/HT2pmsxPiC
Richard Conway RichardPAConway ( View Tweet)
Wow! Walrabenstein et al. RCT of plant-based diet (and exercise and stress management) vs usual care in low-moderate disease activity RA. It worked! But which of the 3 parts of the intervention was responsible? @RheumNow #ACR22 Abstr#1998 https://t.co/X1f07ZWPjU https://t.co/nkM4misfFW
Richard Conway RichardPAConway ( View Tweet)
Yokose et al. Higher risk of mortality in women with gout. Primarily CVD related death. @RheumNow #ACR22 Abstr#1757 https://t.co/Ft3Km8Jw17 https://t.co/uBOUnV4n0Z
Richard Conway RichardPAConway ( View Tweet)
Haibel et al. Intraarticular morphine no different to placebo and inferior to steroid in knee OA. @RheumNow #ACR22 Abstr#1833 https://t.co/9dOlfYMVlj https://t.co/a3uvw3gVw3
Richard Conway RichardPAConway ( View Tweet)